The first line anti-tuberculosis drugs have shown an increasing prevalence of resistance. The higher incidence of TB has led to stronger requirements of other therapies apart from the World Health Organisation recommended Directly Observed Therapy in Short course (DOTS). New drugs highly effective against Mycobacterium tuberculosis (MTB) could enhance the treatment of cases with resistance to first line drugs (isoniazid and rifampicin) and may curtail the extent of present regular regimes. Fluoroquinolones are reasonably effective against Mycobacterium tuberculosis (MTB). They have been used as alternative for some present first-line drugs such as Isoniazid, and have been efficient even in Multi Drug Resistant Tuberculosis. These efforts must be further enhanced to ensure ultimate success in discovering, developing, and delivering drastically improved therapies for tuberculosis patients.
The paper’s primary contribution is finding that Moxifloxacin may curtail the time duration and adverse events in the case of multi drug resistant tuberculosis.
A. Garcia-Tapia, J. C. Rodriguez, M. Ruiz, and G. Royo, "Action of fluoroquinolones and linezolid on logarithmic- and stationary-phase culture of mycobacterium tuberculosis," Chemotherapy, vol. 50, pp. 211–213, 2004.
P. Ball, "Safety profile of oral and intravenous moxifloxacin: Cumulative data from clinical trials and post marketing studies," Clinical Therapeutics, vol. 26, pp. 940–950, 2004.
CDC, "Controlling tuberculosis in the United States: Recommendations from the American thoracic society, CDC, and the infectious diseases society of America," MMWR, vol. 54. Available www.cdc.gov/mmwr/preview/mmwrhtml/rr5412a1.htm, 2005.
R. S. Dawe, S. H. Ibbotson, J. B. Sanderson, E. M. Thomson, and J. Ferguson, "A randomized controlled trial of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity," British Journal of Dermatology, vol. 149, pp. 1232–1241, 2003.
J. C. Rodriguez, M. Ruiz, M. Lopez, and G. Royo, "In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against mycobacterium tuberculosis," International Journal Antimicrobial Agents, vol. 20, pp. 464–467, 2002.
K. Tahaoglu and T. L. Torun, "The treatment of multidrug-resistant tuberculosis in Turkey," New England Journal of Medicine, vol. 345, pp. 170–174, 2001.
A. Lubasch, R. Erbes, H. Mauch, and H. Lode, "Moxifloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy," European Respiratory Journal, vol. 17, pp. 641–646, 2001.
W. W. Yew, C. K. Chan, and C. C. Leung, "Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: Preliminary results of a retrospective study from Hong Kong," Chest, vol. 124, pp. 1476–1481, 2003.
R. D. Gosling, L. O. Uiso, N. E. Sam, E. Bongard, E. G. Kanduma, and M. Nyindo, "The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis," American Journal of Respiratory Critical Care Medicine, vol. 168, pp. 1342–1345, 2003.
J. S. Mukherjee and M. L. Rich, "Programmes and principles in treatment of multi-drug resistant tuberculosis," Lancet, vol. 363, pp. 474–481, 2004.
L. Richeldi and M. Covi, "Clinical use of levofloxacin in the long-term treatment of drug resistant tuberculosis," Archives of Chest Diseases, vol. 57, pp. 39–43, 2002.